Immunotherapy Combinations for Cancer

Recruiting in Palo Alto (17 mi)

+48 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Bristol-Myers Squibb

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.

Eligibility Criteria

This trial is for adults with certain advanced solid cancers that have spread and can't be removed by surgery. Participants should be relatively healthy (ECOG status of 0 or 1) and have a tumor that can be measured. They must also provide tissue samples for research. People with brain metastases, lung inflammation history, active cancer in the last two years (except some skin cancers), or recent serious neurological issues cannot join.

Inclusion Criteria

I have tumor tissue available for testing.

I am fully active or can carry out light work.

My cancer is advanced, cannot be surgically removed, and its size can be measured.

Exclusion Criteria

I have had lung inflammation or scarring before.

I haven't had any cancer except for treated skin cancer in the last 2 years.

My cancer has spread to my brain or is only active there.

+1 more

Participant Groups

The study tests combinations of immunotherapy drugs: relatlimab with nivolumab and BMS-986205, or relatlimab with nivolumab and ipilimumab. It aims to find out how safe these combinations are and how well they work against different types of advanced tumors in patients who haven't had immunotherapy before as well as those who have.

2Treatment groups

Experimental Treatment

Group I: Arm BExperimental Treatment3 Interventions

Relatlimab + Nivolumab + Ipilimumab

Group II: Arm AExperimental Treatment3 Interventions

Relatlimab + Nivolumab + BMS-986205